Q75 – 85: Engraftment Syndrome

!The Engraftment Syndrome section can only be completed on the 100-day follow-up form. These questions will be skipped for all subsequent reporting periods.

*Combined Follow-Up
In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions do not apply and are disabled.

Questions 75 – 76: Did engraftment syndrome occur?

Engraftment syndrome typically occurs during neutrophil recovery post-HCT and is characterized by capillary leak syndrome, non-infectious fever, erythrodermatous skin rash, and non-cardiogenic pulmonary edema. Engraftment syndrome is usually seen following autologous transplants but can occur after allogeneic transplants. It is associated with increased transplant mortality, generally from pulmonary and associated multi-organ failure. Corticosteroid therapy is often an effective treatment for engraftment syndrome, mainly for the treatment of pulmonary symptoms.

Indicate whether the recipient developed engraftment syndrome.

If the recipient developed engraftment syndrome during the reporting period, report Yes and indicate the date of diagnosis. If the recipient did not develop engraft syndrome, report No.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Questions 77 – 78: Specify the symptoms of engraftment syndrome (check all that apply)

Specify the engraftment syndrome symptoms the recipient developed in the reporting period. Check all that apply. If Other symptom is selected, specify the symptom present.

Questions 79 – 82: Was a biopsy performed?

Indicate Yes or No if a biopsy was performed to evaluate engraftment syndrome. If Yes, specify the site(s) and indicate whether documentation (pathology report) was attached to the form in FormsNet3 or otherwise submitted to the CIBTMR. If Other site is selected, specify the biopsy site.

For further instructions on how to attach documents in FormsNet3^SM, refer to the FormsNet3 Training Guide. If no biopsies were done to evaluate for engraftment syndrome, report No.

Questions 83 – 84: Specify therapy given for engraftment syndrome (check all that apply)

Specify any therapy given for engraftment syndrome. If Other therapy is selected, specify the treatment(s) administered. If therapy was not given, select None.

Question 85: Did engraftment syndrome resolve?

Indicate whether engraftment syndrome resolved during the reporting period. If engraftment syndrome was still present on the date of contact, report No.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.